Literature DB >> 20086088

Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.

Donna E Akiyoshi1, Abhineet S Sheoran, Curtis M Rich, L Richard, Susan Chapman-Bonofiglio, Saul Tzipori.   

Abstract

5C12 HuMAb is a human monoclonal antibody against the A subunit of Shiga toxin 2 (Stx2). We have previously shown that 5C12 HuMAb effectively neutralizes the cytotoxic effects of this toxin by redirecting its transport within the cell and also by neutralizing the toxin's ability to inhibit protein synthesis. The 5C12 HuMAb and its recombinant IgG1 version protect mice at a dose of 0.6 microg against a lethal challenge of Stx2. The contribution of the Fc region to this observed neutralization activity of the 5C12 antibody against Stx2 was investigated in this study. Using recombinant DNA technology, 5C12 isotype variants (IgG1, IgG2, IgG3, and IgG4) and antibody fragments [Fab, F(ab')(2)] were expressed in Chinese hamster ovary cells and evaluated in vitro and in vivo. All four 5C12 isotype variants showed protection in vitro, with the IgG3 and IgG4 variants showing the highest protection in vivo. The Fab and F(ab')(2) fragments also showed protection in vitro but no protection in the mouse toxicity model. Similar results were obtained for a second HuMAb (5H8) against the B subunit of Stx2. The data suggest the importance of the Fc region for neutralization activity, but it is not clear if this is related to the stability of the full-length antibody or if the Fc region is required for effective elimination of the toxin from the body.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086088      PMCID: PMC2825921          DOI: 10.1128/IAI.00867-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

Review 1.  Glycan mimicry as a basis for novel anti-infective drugs.

Authors:  G Mulvey; P I Kitov; P Marcato; D R Bundle; G D Armstrong
Journal:  Biochimie       Date:  2001-08       Impact factor: 4.079

Review 2.  Shiga toxins and apoptosis.

Authors:  Rama P Cherla; Sang-Yun Lee; Vernon L Tesh
Journal:  FEMS Microbiol Lett       Date:  2003-11-21       Impact factor: 2.742

3.  Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system.

Authors:  Kazuyuki Inoue; Kunihiko Itoh; Hiroshi Nakao; Tae Takeda; Toshio Suzuki
Journal:  Tohoku J Exp Med       Date:  2004-08       Impact factor: 1.848

4.  Monoclonal antibody 11E10, which neutralizes shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin.

Authors:  Michael J Smith; Angela R Melton-Celsa; James F Sinclair; Humberto M Carvalho; Cory M Robinson; Alison D O'Brien
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

5.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

6.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 9.  Infection by Shiga toxin-producing Escherichia coli: an overview.

Authors:  Mohamed A Karmali
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

10.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more
  13 in total

1.  Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Authors:  Stylianos Bournazos; Siu-Kei Chow; Nareen Abboud; Arturo Casadevall; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

Review 2.  A Comprehensive Review: Development of Electrochemical Biosensors for Detection of Cyanotoxins in Freshwater.

Authors:  Vasileia Vogiazi; Armah de la Cruz; Siddharth Mishra; Vesselin Shanov; William R Heineman; Dionysios D Dionysiou
Journal:  ACS Sens       Date:  2019-05-14       Impact factor: 7.711

3.  Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.

Authors:  Somayeh Ghotloo; Mohammad Mehdi Amiri; Jalal Khoshnoodi; Ebrahim Abbasi; Mahmood Jeddi-Tehrani; Forough Golsaz-Shirazi; Fazel Shokri
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

4.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

Review 5.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

Review 6.  Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs.

Authors:  Eran Diamant; Amram Torgeman; Eyal Ozeri; Ran Zichel
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

7.  Antibody to ricin a chain hinders intracellular routing of toxin and protects cells even after toxin has been internalized.

Authors:  Kejing Song; R Ranney Mize; Luis Marrero; Miriam Corti; Jason M Kirk; Seth H Pincus
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

8.  Single Chain Variable Fragments Produced in Escherichia coli against Heat-Labile and Heat-Stable Toxins from Enterotoxigenic E. coli.

Authors:  Christiane Y Ozaki; Caio R F Silveira; Fernanda B Andrade; Roberto Nepomuceno; Anderson Silva; Danielle D Munhoz; Bruno B Yamamoto; Daniela Luz; Patrícia A E Abreu; Denise S P Q Horton; Waldir P Elias; Oscar H P Ramos; Roxane M F Piazza
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

Review 9.  Recent developments in antibody-based assays for the detection of bacterial toxins.

Authors:  Kui Zhu; Richard Dietrich; Andrea Didier; Dominik Doyscher; Erwin Märtlbauer
Journal:  Toxins (Basel)       Date:  2014-04-11       Impact factor: 4.546

10.  Role of Fc in antibody-mediated protection from ricin toxin.

Authors:  Seth H Pincus; Anushka Das; Kejing Song; Grace A Maresh; Miriam Corti; Jody Berry
Journal:  Toxins (Basel)       Date:  2014-05-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.